Glioma News and Research RSS Feed - Glioma News and Research

Glioma is a cancer of the brain that begins in glial cells (cells that surround and support nerve cells).
Tocagen's Toca 511 & Toca FC receives FDA orphan drug designation for treatment of glioblastoma

Tocagen's Toca 511 & Toca FC receives FDA orphan drug designation for treatment of glioblastoma

Tocagen Inc., a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to the company's lead immuno-oncology product candidate, Toca 511 & Toca FC, for the treatment of glioblastoma. [More]
Regen BioPharma implements gene silencing technology in killing cancer stem cells

Regen BioPharma implements gene silencing technology in killing cancer stem cells

Regen BioPharma Inc. reported today the successful implementation of its gene silencing technology, covered by patent # 8,263,571, in killing cancer stem cells. [More]
Complete removal of visible tumor improves outcomes in children with high-grade glioma

Complete removal of visible tumor improves outcomes in children with high-grade glioma

For children with aggressive brain cancers called high-grade gliomas (HGG), the chances of survival are improved when surgery is successful in eliminating all visible cancer, reports a study in the September issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. [More]
New UBC research reveals alternative route to rein in glioma cancer cells

New UBC research reveals alternative route to rein in glioma cancer cells

New UBC research into brain cancer suggests treatments should target the cells around a tumor to stop it from spreading. [More]
Structural brain changes found in chemoradiation-treated glioblastoma patients

Structural brain changes found in chemoradiation-treated glioblastoma patients

US researchers find evidence of marked and progressive brain atrophy during standard chemoradiation therapy in patients with glioblastoma. [More]
Apogenix signs licensing agreement with CANbridge to commercialize APG101 in China, Macao and Hong Kong

Apogenix signs licensing agreement with CANbridge to commercialize APG101 in China, Macao and Hong Kong

Apogenix, a next generation immuno-oncology company, announced today that it has entered into an exclusive licensing agreement with CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, for the development and commercialization of lead immuno-oncology drug candidate APG101 in China, Macao, and Hong Kong. [More]
Cedars-Sinai scientists identify genes responsible for tumor growth in high grade brain tumors

Cedars-Sinai scientists identify genes responsible for tumor growth in high grade brain tumors

After generating new brain tumor models, Cedars-Sinai scientists in the Board of Governors Regenerative Medicine Institute identified the role of a family of genes underlying tumor growth in a wide spectrum of high grade brain tumors. [More]
Researchers make significant progress in improving survival of adult patients with low-grade gliomas

Researchers make significant progress in improving survival of adult patients with low-grade gliomas

Using clinical data collected over the past decade through a U.S. cancer registry, researchers at the University of California, San Diego School of Medicine demonstrated that significant strides have been made in improving the survival of adult patients with low-grade gliomas, a slow-growing yet deadly form of primary brain cancer. [More]
Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

Study may predict which glioblastoma patients may respond well to dasatinib drug treatment

Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit. Researchers at Mayo Clinic, who conducted one of those clinical trials, believe they know why dasatinib failed — and what to do about it. [More]
Detroit-area patients contribute to national study that redefines diagnosis, treatment of glioma

Detroit-area patients contribute to national study that redefines diagnosis, treatment of glioma

Sixty-seven patients from the Hermelin Brain Tumor Center at Henry Ford Hospital and their families made important contributions to a national cancer study that proposes a change in how some brain tumors are classified - and ultimately treated. [More]
Molecular classifications of low-grade gliomas proposed

Molecular classifications of low-grade gliomas proposed

Two research teams have independently proposed molecular classification systems for grade II and III glioma based on three tumour markers, with each category displaying distinct clinical features and outcomes. [More]
Scientists find new way of classifying brain cancers

Scientists find new way of classifying brain cancers

Not all brain cancers are the same but together they represent a deadly disease that has been difficult to identify and treat. Scientists at multiple institutions have found a new way of classifying brain cancers that could very well change how the illness is diagnosed and treated. [More]
Researchers generate computer models for targeted drug therapy on DIPG cancer cells

Researchers generate computer models for targeted drug therapy on DIPG cancer cells

The results of a recent study on targeted therapy of a specific type of brain cancer were published by Nature Medicine showing specific progress in cancer treatment. [More]
NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, over the weekend in Chicago released promising new data on their Phase I trial of DCVax-Direct for direct injection into all types of inoperable solid tumors. [More]
Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

Researchers identify key driver mutations in glioma samples that confirm tumor heterogeneity

Caris Life Sciences today announced the presentation of data from a study in which researchers identified biomarker changes, including key driver mutations, in 89% of metachronous paired glioma tumors, indicating changes in response to therapy as the disease progresses. [More]
Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, presented additional preclinical data at the American Association of Cancer Research (AACR) Advances in Brain Cancer Research Conference on the potential for its lead product candidate VAL-083 (dianhydrogalactitol) to treat patients with temozolomide-resistant glioblastoma multiforme (GBM). [More]
Brain Tumor Biotech Summit held in Manhattan on 29 May, 2015

Brain Tumor Biotech Summit held in Manhattan on 29 May, 2015

Voices Against Brain Cancer, a national non-profit organization committed to finding a cure for brain cancer and brain tumors, and the Feinstein Institute for Medical Research in Long Island, will be hosting a Brain Tumor Biotech Summit on Friday, May 29th, 2015 at Lenox Hill Hospital's Einhorn Auditorium in Manhattan. [More]
Researchers identify chemical pathway associated with seizures, shorter survival in patients with malignant glioma

Researchers identify chemical pathway associated with seizures, shorter survival in patients with malignant glioma

Researchers at the University of Alabama at Birmingham have identified a chemical pathway that may be associated with seizures and shorter patient survival in some patients with malignant glioma, the most common and deadly form of brain tumor. In findings published May 27 in Science Translational Medicine, the researchers suggest that a transporter known as SXC is responsible for boosting levels of glutamate in the brains of some glioma patients. [More]
New nationwide survey shows steady increase in pediatric patients treated with proton radiation therapy

New nationwide survey shows steady increase in pediatric patients treated with proton radiation therapy

Results from a new nationwide survey announced today indicate a steady increase in the number of pediatric patients who are being treated with proton radiation therapy for cancerous and non-cancerous tumors. [More]
nTMS analysis of motor areas improves prognosis of patients with malignant brain tumors

nTMS analysis of motor areas improves prognosis of patients with malignant brain tumors

A method known as navigated transcranial magnetic stimulation (nTMS) has been gaining importance in neurosurgery for some time now. [More]
Advertisement
Advertisement